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Modelling the lifetime cost-effectiveness of
radical prostatectomy, radiotherapy and
active monitoring for men with clinically
localised prostate cancer from median 10-
year outcomes in the ProtecT randomised
trial
S. Sanghera1* , S. Mohiuddin1,2, J. Coast1, K. Garfield1,3, S. Noble1, C. Metcalfe3, J. A. Lane3,4, E. L. Turner4, D. Neal5,
F. C. Hamdy5†, R. M. Martin4,6†, J. L. Donovan2,4† and for the ProtecT study group
Abstract
Background: Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-
year data from the largest randomised controlled trial to date (ProtecT), the lifetime cost-effectiveness of three
major treatments (radical radiotherapy, radical prostatectomy and active monitoring) was explored according to age
and risk subgroups.
Methods: A decision-analytic (Markov) model was developed and informed by clinical input. The economic
evaluation adopted a UK NHS perspective and the outcome was cost per Quality-Adjusted Life Year (QALY) gained
(reported in UK£), estimated using EQ-5D-3L.
Results: Costs and QALYs extrapolated over the lifetime were mostly similar between the three randomised
strategies and their subgroups, but with some important differences. Across all analyses, active monitoring was
associated with higher costs, probably associated with higher rates of metastatic disease and changes to radical
treatments.
When comparing the value of the strategies (QALY gains and costs) in monetary terms, for both low-risk prostate
cancer subgroups, radiotherapy generated the greatest net monetary benefit (£293,446 [95% CI £282,811 to £299,
451] by D’Amico and £292,736 [95% CI £284,074 to £297,719] by Grade group 1). However, the sensitivity analysis
highlighted uncertainty in the finding when stratified by Grade group, as radiotherapy had 53% probability of cost-
effectiveness and prostatectomy had 43%. In intermediate/high risk groups, using D’Amico and Grade group > = 2,
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prostatectomy generated the greatest net monetary benefit (£275,977 [95% CI £258,630 to £285,474] by D’Amico
and £271,933 [95% CI £237,864 to £287,784] by Grade group). This finding was supported by the sensitivity analysis.
Prostatectomy had the greatest net benefit (£290,487 [95% CI £280,781 to £296,281]) for men younger than 65 and
radical radiotherapy (£201,311 [95% CI £195,161 to £205,049]) for men older than 65, but sensitivity analysis showed
considerable uncertainty in both findings.
Conclusion: Over the lifetime, extrapolating from the ProtecT trial, radical radiotherapy and prostatectomy
appeared to be cost-effective for low risk prostate cancer, and radical prostatectomy for intermediate/high risk
prostate cancer, but there was uncertainty in some estimates. Longer ProtecT trial follow-up is required to reduce
uncertainty in the model.
Trial registration: Current Controlled Trials number, ISRCTN20141297: http://isrctn.org (14/10/2002); ClinicalTrials.
gov number, NCT02044172: http://www.clinicaltrials.gov (23/01/2014).
Keywords: Prostate cancer, ProtecT trial, Lifetime cost-effectiveness, Active monitoring, Radiotherapy, Prostatectomy
Background
Prostate cancer is the most common cancer in men in
Europe and the second most common cancer in men
worldwide [1], placing a considerable burden on health-
care resources globally. Thirteen percent of all cancer
deaths in men in the UK are attributable to prostate can-
cer [1]. However, due to the typically slow natural pro-
gression of the disease, many men with prostate cancer
die of other causes, which has led to an international de-
bate about the optimal disease management strategy [2].
UK guidelines developed by the National Institute for
Health and Care Excellence (NICE) were recently
updated to include evidence from the Prostate Testing
for Cancer and Treatment (ProtecT) trial [3]. The guide-
lines recommend treatment stratified according to the
D’Amico risk categories [4, 5]. NICE recommend offer-
ing a choice of treatment (active surveillance, prostatec-
tomy and radiotherapy) for men with low risk, localised
prostate cancer. For men with intermediate risk, local-
ised prostate cancer, NICE recommend that radical
treatment (either surgery or radiotherapy) be offered,
but active surveillance should be considered for men
who do not want radical treatment. For high risk local-
ised prostate cancer, radical treatment should be offered
rather than active surveillance. However, evidence from
a direct comparison of the long-term cost-effectiveness
of radical prostatectomy, radical radiotherapy and active
monitoring for men with localised prostate cancer was
not available for all men with localised prostate cancer
or by risk stratification, and the recommendations were
therefore based on limited direct evidence of cost-
effectiveness.
ProtecT is the largest randomised controlled trial to
date comparing the effectiveness and cost-effectiveness
of active monitoring, radical prostatectomy or external
beam 3D conformal radiotherapy with neo-adjuvant
androgen deprivation for men with clinically localised
prostate cancer detected following PSA testing and
transrectal ultrasound guided biopsies [3]. The primary
analysis was conducted at a median follow-up period of
10 years.
The aim was to determine the lifetime cost-
effectiveness of managing localised prostate cancer
according to the following sub-groups: i) age: less than
65 years old, 65 years and older; ii) the D’Amico prostate
cancer risk stratification groups: low (PSA < 10 ng/ml,
Gleason score < =6, T1c/T2a) or intermediate/high risk
((PSA > =10 ng/ml & < 20 ng/ml, Gleason score 3 + 4 = 7
or 4 + 3 = 7, T2b) or (PSA > =20 ng/ml, Gleason score > =
8, T2c)) [4] and iii) by Gleason Grade Group (GGG):
low: GGG 1; or intermediate/high risk (GGG > =2) [6]
Methods
To estimate the lifetime cost-effectiveness of manage-
ment strategies for clinically localised prostate cancer ac-
cording to risk group, a model-based cost-effectiveness
analysis was conducted using median 10-year follow-up
data from the ProtecT trial. The outcome was cost per
quality-adjusted life year (QALY) gained based on EQ-
5D-3L. A UK NHS perspective was adopted.
ProtecT trial
The ProtecT trial methods and median 10-year out-
comes are reported in detail elsewhere [3, 7] At a me-
dian of 10-years’ follow up, the ProtecT trial reported no
evidence of differences in prostate-cancer specific mor-
tality [8] between the three management strategies (all
approximately 1%), but the rate of disease progression
(evidence of clinical progression (T3 or T4 or the initi-
ation of long-term androgen deprivation therapy (ADT))
and metastases in the prostatectomy and radiotherapy
group was half that of men in the active monitoring
group (6% compared with 2–3%) [9]. There was no evi-
dence of differences in generic health status (mental or
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physical health, anxiety or depression) between the
groups, but prostatectomy had greater adverse effects on
sexual function and continence, and radiotherapy on
sexual and bowel function [10] compared with active
monitoring over the 6-year data collection period.
Cost-effectiveness model
We developed a state transition Markov model in
Microsoft Excel, programmed in Visual Basic for Appli-
cations, to estimate the lifetime cost-effectiveness of al-
ternative treatment strategies for men with clinically
localised prostate cancer. Clinical input from the Pro-
tecT investigators on the pathways followed by men in
the ProtecT trial informed the model structure (Fig. 1).
In the model men could: remain in a stable or managed
prostate cancer state where men are receiving one of the
randomised strategies; experience local, or distant dis-
ease progression (metastases). The disease progression
and metastatic states followed the same definitions as in
the ProtecT trial: evidence of clinical progression (T3 or
T4 disease or the initiation of long-term androgen
deprivation therapy (ADT) or presence of metastasis
(M1, N1), PSA > 100 μg/ml) [7]. From any state, a man
could die of causes other than prostate cancer. Men
might remain in the same state or move between health
states at annual intervals, reflecting the slow progressive
nature of most prostate cancers.
Parameter estimation
Model inputs for the transition of men between health
states were estimated from the ProtecT trial patient-
level data (Tables S1, S3, S5 in supplementary material),
with starting ages of 50–69 years, and applied to the
model cohort with a starting age of 50 years. To esti-
mate death due to other causes, deaths related to
prostate cancer (defined as ‘ICD C61: malignant
neoplasm of prostate’) were removed from the UK
national life tables. As expected, the estimate of death
due to other causes increased as the age of men in
the model increased.
The following assumptions were made based on
clinical expertise within the ProtecT team, and were
agreed prior to conducting the analysis:
 The initial and subsequent treatment received by
men in the ‘stable’, ‘disease progression’ and
‘metastatic’ states followed what was observed in
the trial;
 The same quality of life and resource use observed
during trial follow-up for each health state in the
model was assumed to continue beyond the first ten
years;
 For simplicity, it was only possible for a man to die
from prostate cancer from the metastatic state in
the model. While it is possible for a man to die from
local progression, this is uncommon;
 The same costs were assumed to have occurred in
the last year of life across the treatment strategy;
 The disease progression state comprised men found
to have tumour stage T3-T4, or those treated with
hormone therapy, or where clinicians indicated that
the disease had progressed locally.
Fig. 1 Schematic diagram of the Markov model
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Quality of life
Self-reported quality of life data were collected in the
ProtecT trial using EQ-5D-3L at baseline (prior to diag-
nosis), 6 months, and yearly thereafter [9]. Quality of life
values were assigned to each health state and the algo-
rithm applied for EQ-5D-3L UK value set [11] (Tables
S2, S4, S6 in supplementary material). Quality of life
scores were calculated by averaging the score of men in
a health state at any given time. For missing scores, the
mean of the adjacent years (prior and following) were
used. The outcome was reported as QALYs.
Resource use and costs
Costs were presented from a UK NHS perspective. Data
on healthcare resource use were collected from men and
a local medical records review in the within-trial analysis
[12]. Data on costs and resource use from the trial were
collated and analysed according to the randomised treat-
ment arm (Tables S2, S4, S6 in supplementary material).
The general healthcare costs for the groups included in-
patient and day-case hospital stays, outpatient hospital
visits, GP visits, healthcare staff costs and medication
costs. Costs and outcomes were discounted at 3.5%
according to UK NICE guidelines, as the model time
horizon extended beyond one year [13]. All costs were
reported in 2014–15 price year in UK (£) sterling. As
2015 was the data lock point.
Analysis
The cost-effectiveness analysis provided an assessment
of differences in costs and outcomes between the three
treatment options over a man’s lifetime from the time a
diagnosis of prostate cancer was made. As three manage-
ment strategies were compared, the results are presented
as net monetary benefits. The net monetary benefit is
the value of the strategy in monetary terms at a specific
willingness to pay threshold per unit of benefit gained.
An average UK (NICE) willingness-to-pay threshold of
£20,000 per QALY gained was used. The strategy with
the greatest net monetary benefit ((Benefit × threshold)
−Cost) is considered to be the most cost-effective strat-
egy. When comparing the strategies, the evidence that
the cost-effectiveness of strategies differs is weak if the
confidence intervals overlap.
Two types of parametric proportional hazards
models were used to extrapolate annual mean transi-
tion estimates beyond the trial. Weibull models,
which assume a changing rate of transition over time,
had the best fit for stable to local disease progression
and stable to metastases transitions. The exponential
models, which assume a constant rate of transition,
fitted the data best for local disease progression to
metastases and metastases to death from prostate
cancer. Patient-level trial data were used to fit the
models. For the quality of life data, we used the aver-
age value across the three management strategies for
each state; therefore, the impact on quality of life is
captured through the proportions of men entering
each state by management strategy.
Analysis was carried out by intention-to-treat. The
following analyses were performed:
 Stratification by age to compare cost-effectiveness
for men less than 65 years old and 65 years or older
(Table S1–2 in supplementary material).
 Stratification by D’Amico risk groups to compare
cost-effectiveness for low risk and combined
intermediate/high risk groups (Table S3–4 in
supplementary material).
 Stratification by Grade groups to compare cost-
effectiveness for low risk (GGG 1) and combined
intermediate/high risk groups (GGG > = 2) (Table
S5–6 in supplementary material). Intermediate and
high risk subgroups were combined due to small
numbers.
 A probabilistic sensitivity analysis of the above
groups to provide a more comprehensive assessment
of uncertainty, as all the relevant model inputs are
changed simultaneously rather than changing one
input at a time. For each model input, a distribution
of plausible range of values was assigned. A value
was then randomly drawn from the assigned
distribution. This process was repeated 10,000 times
to obtain a measure of uncertainty around the
results, which are presented as cost-effectiveness
acceptability curves (CEACs) to illustrate how the
willingness-to-pay threshold for an additional QALY
affects the probability that a management strategy is
considered cost-effective.
Results
Table 1 presents the cost-effectiveness results for the
different risk groups and Fig. 2 presents the uncer-
tainty analysis in the CEAC. Costs and QALYs were
similar across treatment groups with some key
differences.
Age thresholds
Over a lifetime, both QALYs gained and costs were
greater in men who were younger than 65 years than
men older than 65 years. In the age group analysis,
there was considerable uncertainty in the results. In
men aged less than 65 years, prostatectomy generated
the greatest net monetary benefit (£290,487; [95% CI
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£280,781, £296,281]), but the net monetary benefit
was similar for active monitoring (£290,279; [95% CI
£281,895, £295,127]). The probabilistic sensitivity ana-
lysis (Fig. 2) showed that from a 0-£25,000 per QALY
gained decision-maker threshold, prostatectomy was
more likely to be cost-effective with a probability of
~ 40% at £20,000 per QALY gained. However, this
probability differed only by 10% compared to the
other strategies as the likelihood of active monitoring
and radiotherapy being cost-effective was approxi-
mately 30% for both strategies at the same decision-
maker threshold. For men who were older than 65
years old, radiotherapy generated the greatest net
monetary benefit (£201,311; [95% CI £195,161 to
£205,049]), but the result was similar to prostatec-
tomy (£201,052; [95% CI £195,294 to £204,579]). The
probabilistic sensitivity analysis (Fig. 2) showed that
radiotherapy was more likely to be cost-effective up
to a willingness to pay threshold of £27,000 per
QALY gained, but beyond this point prostatectomy
becomes more cost-effective. At a threshold of £20,
000 per QALY gained, radiotherapy had a 55%
probability of being cost-effective compared to 45%
for prostatectomy.
Low risk localised prostate cancer
Over a lifetime, in men with low risk prostate cancer
(according to D’Amico risk stratification), radiotherapy
was the least costly strategy and generated greater
QALYs overall than both active monitoring (£2455 and
0.08 QALY difference) and prostatectomy (£500 and
0.09 QALY difference). The difference in QALY benefit
generated by radiotherapy was approximately equivalent
to an additional month in perfect health over a man’s
lifetime. Radiotherapy therefore marginally generated
the greatest net monetary benefit (£293,446; [95% CI
£282,811, £299,451]) in low risk prostate cancer and
these results were supported by the CEAC (Fig. 2) that
Table 1 Cost-effectiveness results from age and risk stratification analyses
Strategy Mean lifetime cost per patient1 Mean lifetime QALYs per patient1 NMB2 at £20,000 per QALY (95% CI)
Age group < 65 years
Active monitoring (AM)3 £15,359 15.36 £290,279 (£281,895 to £295,127)
Radical prostatectomy (RP) £12,939 15.25 £290,487 (£280,781 to £296,281)*
Radiotherapy (RT) £14,746 15.32 £289,754 (£278,620 to £296,202)
Age group ≥ 65 years
Active monitoring (AM) £9444 10.23 £194,153 (£186,516 to £199,781)
Radical prostatectomy (RP)4 £10,283 10.61 £201,052 (£195,294 to £204,579)
Radiotherapy (RT) £9174 10.57 £201,311 (£195,161 to £205,049)*
D’Amico low risk group
Active monitoring (AM) £14,027 15.29 £289,965 (£279,855 to £296,013)
Radical prostatectomy (RP) £12,072 15.25 £290,967 (£279,084 to £297,907)
Radiotherapy (RT) £11,572 15.34 £293,446 (£282,811 to £299,451)*
D’Amico intermediate/high risk group
Active monitoring (AM) £18,297 14.30 £265,526 (£247,010 to £278,307)
Radical prostatectomy (RP) £15,323 14.70 £275,977 (£258,630 to £285,474)*
Radiotherapy (RT) £15,060 14.35 £268,669 (£246,778 to £282,238)
Grade group - low risk
Active monitoring (AM) £14,144 15.15 £287,565 (£278,750 to £293,382)
Radical prostatectomy (RP) £12,055 15.28 £292,198 (£283,797 to £297,258)
Radiotherapy (RT) £12,041 15.31 £292,736 (£284,074 to £297,719)*
Grade group - intermediate/high risk
Active monitoring (AM) £17,838 13.90 £256,111 (£226,180 to £276,399)
Radical prostatectomy (RP) £17,645 14.78 £271,933 (£237,864 to £287,784)*
Radiotherapy (RT) £16,317 13.54 £248,558 (£207,893 to £274,911)
1 Deterministic analysis; 2 Probabilistic sensitivity analysis; QALYs (quality adjusted life years); NMB (net monetary benefit); CI (confidence interval) based on the
percentile method; 3 AM becomes more cost-effective compared with both RP and RT beyond a willingness-to-pay (WTP) threshold of £24,000 for age subgroup
< 65 years (Fig. 2); 4 RP becomes more cost-effective compared with RT beyond a WTP threshold of £28,000 for age subgroup ≥65 years (Fig. 2); *indicates the
most cost-effective strategy
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Fig. 2 Cost-effectiveness acceptability curves for all analyses
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showed that radiotherapy had the greatest likelihood of
cost-effectiveness at any decision-maker willingness to
pay threshold. At a £20,000 per QALY gained threshold,
radiotherapy had a ~ 60% likelihood when compared to
prostatectomy (~ 30% likelihood) and active monitoring
(~ 10%). When stratified by grade group, in the low risk
GGG, radiotherapy was marginally less costly (£14) and
was associated with marginally more QALY gains (0.03
QALYs) when compared to prostatectomy. However, the
net monetary benefit was similar: £292,736 (95% CI
£284,074 to £297,719) and £292,198 (95% CI £283,797
to £297,719) for radiotherapy and prostatectomy, re-
spectively. The probabilistic sensitivity analysis showed
the extent of the uncertainty in the result as radiother-
apy was only slightly more likely to be cost-effective at
all decision-maker thresholds – reaching ~ 53% for
radiotherapy and ~ 45% for prostatectomy at a £20,000
per QALY gained threshold (Fig. 2).
Intermediate/high risk localised prostate cancer
For both risk groups (D’Amico and GGG), the QALYs
gained were consistently lower in the intermediate/
high risk subgroups when compared to the low risk
groups. Costs varied between management strategies,
ranging between £11,060–£18,297, but were consistently
higher in the intermediate/high risk subgroups when
compared to low risk groups.
In the D’Amico intermediate/high risk group, active
monitoring was more expensive over a lifetime than the
radical strategies, which were similar in cost – prostatec-
tomy cost £15,323 and radiotherapy £15,060. However,
active monitoring and radiotherapy achieved similar
QALY gains, and prostatectomy achieved 0.4 more
QALY gains than active monitoring and 0.35 more
QALYs than radiotherapy. Prostatectomy generated the
greatest net monetary benefit (£275,977; [95% CI £258,
630 to £285,474]) for men with intermediate/high risk
prostate cancer. The probabilistic sensitivity analysis
showed that prostatectomy had a 70% likelihood of be-
ing cost-effective from a willingness to pay threshold of
£5000 per QALY gained upward. Whilst radiotherapy
and active monitoring only had 20 and 10%, respectively
from £15,000 per QALY gained onward. The results for
the intermediate/high risk GGG mirrored that of the
D’Amico intermediate/high risk group with prostatec-
tomy generating the greatest net monetary benefit (£271,
933 [95% CI £237,864 to £287,784]) over a lifetime. The
probabilistic sensitivity analysis showed that prostatec-
tomy had an 80% likelihood of being cost-effective for
the intermediate/high risk GGG compared to 5% for
radiotherapy and 15% for active monitoring from a




Across all analyses, costs and QALYs were similar but
some important differences emerged. From the point of
diagnosis of clinically localized prostate cancer, extrapo-
lating from the median 10-year ProtecT trial findings
over the lifetime of a man, showed that there was
considerable uncertainty in the most cost-effective
management strategy when men were categorised by age
group. For 65-year-old men and younger, all three
management strategies could be considered to be cost-
effective, and for men older than 65 years, either radio-
therapy or prostatectomy could be cost-effective under
the current UK willingness to pay threshold of £20–30,
000 per QALY gained [13]. In all analyses, active moni-
toring was associated with higher costs, which were
probably related to the combined impacts of advanced
disease (20% over an average of 10 years) which requires
new treatments, and a rate of change to radical treat-
ments of over 50% at an average of 10 years from
diagnosis.
When categorised by D’Amico risk group, radiother-
apy appeared most cost-effective for men with low risk
prostate cancer, compared with active monitoring or
radical prostatectomy and when defined as Grade Group
1 alone, either radiotherapy or prostatectomy could be
considered cost-effective. For men with intermediate/
high risk prostate cancer, categorised by D’Amico or
Grade group > = 2, radical prostatectomy was the most
cost-effective strategy across all decision-maker’s willing-
ness to pay thresholds from £5000 per QALY gained.
Comparison with other studies
This is the first study to compare the lifetime cost-
effectiveness of managing clinically localised prostate
cancer by risk group with active monitoring, external
beam radiotherapy with neoadjuvant androgen
deprivation, and radical prostatectomy by extrapolating
from prospectively collected trial data. In continental
Europe other model-based cost-utility analyses have
used cohort studies and extrapolation from an earlier
trial (SPCG-4 which compared watchful waiting to pros-
tatectomy for clinically detected prostate cancer [14]) to
assess the cost-effectiveness of active surveillance or
watchful waiting compared with prostatectomy, radio-
therapy versus prostatectomy, different modalities of
radiotherapy against one another, or different surgical
techniques against one another [15]. A review of these
studies concluded that across all of these studies only
small differences in QALY gains were detected between
strategies and limited evidence supported cost-
effectiveness recommendations of prostatectomy instead
of watchful waiting, brachytherapy over prostatectomy,
and newer treatment approaches above traditional
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methods [15]. The within trial analysis for the ProtecT
trial over a 10-year time period showed that radiother-
apy was the most cost-effective strategy for all men and
the subgroup analysis at 10 years showed that active
monitoring was most cost-effective for low risk men
(D’Amico and Grade group) and men younger than 65
years old. At 10 years, men with intermediate/high risk
(D’Amico and Grade group) and men older than 65
years old, radiotherapy was the most cost-effective strat-
egy [12]. Our lifetime cost-effectiveness results show
that, in the longer term, active monitoring is generally
more expensive than radical strategies due to the rate of
metastasis in active monitoring and treatment change-
over, and beyond the 10-year time period, it does not
appear to be a cost-effective strategy for low risk
subgroups. Furthermore, our results show that despite
prostatectomy being the most expensive strategy in the
intermediate/high risk subgroups, over a lifetime, prosta-
tectomy generates greater QALY gains than radiotherapy
and is the most cost-effective strategy in this subgroup.
Finally, a recent study with a US perspective compared
prostatectomy and radiotherapy to active surveillance for
all men with prostate cancer using published effective-
ness data from the ProtecT trial. The authors concluded
that active surveillance was cost-effective up to 6 years
post-diagnosis, but radiotherapy and prostatectomy were
cost-effective at 10 years. This was due to increased costs
and lower QALYs associated with active surveillance
relative to radical strategies due to the higher rate of me-
tastasis in active surveillance, recurrent prostate biopsy
costs and treatment change. However, the latter finding
was sensitive to the risk of metastasis [16]. None of these
studies assessed the lifetime cost-effectiveness or any
cost-effectiveness, according to different risk subgroups,
of the three major treatment modalities in the PSA-era
using consistent and robust evidence on effectiveness,
costs and quality of life from a single randomised
controlled trial.
Strengths and limitations
The strength of the study is that it is based on data from
the largest randomised controlled trial in localised
prostate cancer to date. The model structure was based
on pathways observed in the trial, supported by clinical
advice, and model assumptions were agreed prior to
analysis. This is the first study to report the lifetime
cost-effectiveness of these strategies for localised
prostate cancer, where all data on resource use and out-
comes used in the model were collected prospectively
alongside a trial and to use EQ-5D-3L to generate
QALYs in localised prostate cancer.
However, there are limitations related both to this
analysis, due to the cost price year relating to the data
lock point of the trial which was now 5 years ago, and
aspects of the ProtecT trial design and timeline. A key
limitation was the reliance on the median 10-year follow
up available in ProtecT, with diagnostic and treatment
pathways designed in the late 1990s. Longer trial follow
up is ongoing to identify potential greater differences in
the rate of development of progression and metastases
and in mortality, that may arise later in the disease path-
way. Further, risk-stratification was based on TRUS-
guided biopsies (standard at the time) rather than the
more accurate but only recently introduced mpMRI
scans [17] in the prostate cancer diagnostic pathway,
upstream of taking prostate biopsies. The mpMRI
enhanced diagnosis of intermediate and high-risk pros-
tate cancer, and reduced detection of low risk disease
might have changed the treatment course for some men.
Treatments have evolved since recruitment to Protect
(1999–2009). Robot-assisted laparoscopic radical prosta-
tectomy is now the prevalent surgical technique, IMRT,
the use of lowdose-rate brachytherapy is increasing and
‘spacers’ are increasingly used in men who receive
radiotherapy, to reduce toxicity of radiation, but there is
currently no evidence that they offer better clinical and
patient reported outcomes [18–20]. Different protocols
of Active Surveillance from the one used in ProtecT
might also have led to different results in terms of rate
of change to radical treatment as well as outcomes.
Finally, given that treatment side-effect profiles are
important and differ between the trial groups [7], the
use of EQ-5D-3L is another limitation, as it is unlikely
to capture issues with urinary, bowel and sexual function
associated with these treatments [9].
Conclusion
The analysis provides evidence that when men with
clinically localised prostate cancer diagnosed by PSA
testing were categorised by age, there is considerable
uncertainty around which management strategy could
be adopted. For men with low risk prostate cancer, of
the three conventional strategies investigated, radical
radiotherapy was more likely to be most cost-effective,
but due to the extent of the uncertainty radical prosta-
tectomy could also be considered, depending on the
patient stratification used to categorise low risk prostate
cancer. The results suggest that based on lifetime cost-
effectiveness results, radical prostatectomy for high or
intermediate risk prostate cancer appears superior to
radiotherapy and active monitoring using median 10-
year data.
The findings provide some support for the NICE
recommendation to offer a choice of management
strategy to men with low risk prostate cancer. For men
with intermediate/high risk cancer, NICE recommends
radical treatment and our findings support surgery.
While the paper outlines the most robust lifetime cost-
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effectiveness analyses from the trial, the limitations
outlined previously suggest that the use of newer diag-
nostic and treatment pathways must be taken into ac-
count. Further longer-term ProtecT trial-follow up with
modelling of the impact of these newer strategies is re-
quired to elucidate more fully the trade-off between
costs and effects for optimal management of screen-
detected localised prostate cancer over a man’s lifetime.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12885-020-07276-4.
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